Yttrium-labelled peptides for therapy of NET

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.

Original languageEnglish
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume39
Issue numberSUPPL.1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Yttrium
Radioisotopes
Peptides
Peptide Receptors
Neoplasms
Bone Marrow
Kidney
Somatostatin Receptors
Octreotide
Therapeutics
Radioactivity
Nausea
Fatigue
Cell Membrane
Neoplasm Metastasis
Amino Acids
DOTA-Tyr(3)-90Y-octreotide

Keywords

  • Y-DOTATOC
  • Neuroendocrine tumours
  • Peptide receptor radionuclide therapy
  • PRRT

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{40f47ce868604d8794482278abdb63f7,
title = "Yttrium-labelled peptides for therapy of NET",
abstract = "Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34{\%} of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.",
keywords = "Y-DOTATOC, Neuroendocrine tumours, Peptide receptor radionuclide therapy, PRRT",
author = "Lisa Bodei and Marta Cremonesi and Grana, {Chiara M.} and Marco Chinol and Baio, {Silvia M.} and Stefano Severi and Giovanni Paganelli",
year = "2012",
month = "2",
doi = "10.1007/s00259-011-2002-y",
language = "English",
volume = "39",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "SUPPL.1",

}

TY - JOUR

T1 - Yttrium-labelled peptides for therapy of NET

AU - Bodei, Lisa

AU - Cremonesi, Marta

AU - Grana, Chiara M.

AU - Chinol, Marco

AU - Baio, Silvia M.

AU - Severi, Stefano

AU - Paganelli, Giovanni

PY - 2012/2

Y1 - 2012/2

N2 - Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.

AB - Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. After 15 years of experience, we can state that PRRT with 90Y- labelled peptides is generally well tolerated. Acute side effects are usually mild, some of which are related to the co-administration of amino acids, such as nausea. Others are related to the radiopeptide, such as fatigue or the exacerbation of an endocrine syndrome, which rarely occurs in functioning tumours. Chronic and permanent effects on target organs, particularly the kidneys and the bone marrow, are generally mild if the necessary precautions are taken. Currently, the potential risk to kidney and red marrow limits the amount of radioactivity that may be administered. However, when tumour masses are irradiated with adequate doses, volume reduction may be observed. 90Y-octreotide has been the most widely used radiopeptide in the first 8-10 years of experience. Unfortunately, all of the published results derive from different and inhomogeneous phase I/II studies. Hence, a direct comparison is virtually impossible to date. Nevertheless, even with these limitations, objective responses are registered in 10-34% of patients. The optimal timing of 90Y-DOTATOC in the management of somatostatin receptor (SSTR)-positive tumours and the way in which it should be integrated with other treatments have yet to be defined, and prospective phase II/III trials comparing the efficacy and toxicity of different schemes of 90Y-DOTATOC administration are still warranted.

KW - Y-DOTATOC

KW - Neuroendocrine tumours

KW - Peptide receptor radionuclide therapy

KW - PRRT

UR - http://www.scopus.com/inward/record.url?scp=84863797969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863797969&partnerID=8YFLogxK

U2 - 10.1007/s00259-011-2002-y

DO - 10.1007/s00259-011-2002-y

M3 - Article

C2 - 22388625

AN - SCOPUS:84863797969

VL - 39

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - SUPPL.1

ER -